학술논문
Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer.
Document Type
Article
Author
Source
MedComm; May2024, Vol. 5 Issue 5, p1-10, 10p
Subject
Language
ISSN
26882663
Abstract
Copyright of MedComm is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)